Arzneimittel-Forschung · 1995
[Ranitidine and amoxicillin for eradication of Helicobacter pylori in patients with duodenal ulcer].
Клиническое исследованиеСравнительное исследованиеСтатьяМногоцентровое исследованиеРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dettmer A
Аннотация
BACKGROUND: The results of many clinical studies have indicated that the eradication of Helicobacter pylori leads to a reduction in ulcer relapse.
METHODS: The aim of this double-blind, randomized, multicenter comparative study in 196 patients with H. pylori positive duodenal ulcer was to examine the efficacy and safety of two eradication therapies with ranitidine. The patients were treated daily with 4 x 150 mg ranitidine (CAS 66357-35-5, Sostril, Zantic) combined with 4 x 500 mg amoxicillin (CAS 26787-78-0, Amoxypen) (group 1) or 4 x 300 mg ranitidine (Sostril 300, Zantic 300) combined with 4 x 500 mg amoxicillin (group 2) for two weeks and during next two weeks with 300 mg ranitidine only.
RESULTS: The final endoscopic investigation 6 weeks yielded healing rates of 90% (group 1) or 96% (group 2). Histopathological examination/urease test of biopsy showed successful eradication of H. pylori in 65%/60% (group 1) or 63%/69% (group 2) of patients. The treatment therapies were generally well or very well tolerated. Adverse events required drug withdrawal only in 3 patients (1.5%).
CONCLUSION: A combination with ranitidine and amoxicillin is an effective and well tolerated therapy in H. pylori infected duodenal ulcer patients. The eradication rate does not seem to be further improved by a ranitidine dose higher than 600 mg daily.
METHODS: The aim of this double-blind, randomized, multicenter comparative study in 196 patients with H. pylori positive duodenal ulcer was to examine the efficacy and safety of two eradication therapies with ranitidine. The patients were treated daily with 4 x 150 mg ranitidine (CAS 66357-35-5, Sostril, Zantic) combined with 4 x 500 mg amoxicillin (CAS 26787-78-0, Amoxypen) (group 1) or 4 x 300 mg ranitidine (Sostril 300, Zantic 300) combined with 4 x 500 mg amoxicillin (group 2) for two weeks and during next two weeks with 300 mg ranitidine only.
RESULTS: The final endoscopic investigation 6 weeks yielded healing rates of 90% (group 1) or 96% (group 2). Histopathological examination/urease test of biopsy showed successful eradication of H. pylori in 65%/60% (group 1) or 63%/69% (group 2) of patients. The treatment therapies were generally well or very well tolerated. Adverse events required drug withdrawal only in 3 patients (1.5%).
CONCLUSION: A combination with ranitidine and amoxicillin is an effective and well tolerated therapy in H. pylori infected duodenal ulcer patients. The eradication rate does not seem to be further improved by a ranitidine dose higher than 600 mg daily.